Latest Qrxpharma Ltd (QRXPF) Headlines Century2
Post# of 3
Posted On: 03/11/2014 3:44:12 AM
Latest Qrxpharma Ltd (QRXPF) Headlines
Century21.com Is The No. 1 Most Visited Real Estate Franchise Website
PR Newswire - Thu Jan 16, 8:08AM CST
Century 21 Real Estate LLC, the franchisor of the world's largest residential real estate sales organization, announced today that its website - century21.com - has become the No. 1 "most visited" real estate franchise website. According to comScore, Inc., a global leader in digital measurement and analytics, century21.com attracted more unique visitors than any other real estate franchise brand site in every month of 2013. In fact, century21.com holds a commanding lead in the number of unique website visitors in 2013 with 25.3 million for the entire year, which was approximately 10 million unique visitors higher than the next-closest national franchise brand. In a year where the industry average for all real estate sites was a 1% gain in total unique website visitors, CENTURY 21 posted a 49% year-over-year increase.
Global Moderate Pain Pipeline Review Report - H2 2013
M2 - Fri Dec 20, 8:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/xlmgdg/moderate_pain) has announced the addition of the "Moderate Pain - Pipeline Review, H2 2013" report to their offering. 'Moderate Pain - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Moderate Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Moderate Pain. Scope - A snapshot of the global therapeutic scenario for Moderate Pain. - A review of the Moderate Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Moderate Pain pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Involved in Moderate Pain Therapeutics Development - Nektar Therapeutics - Esteve Group - Pain Therapeutics, Inc. - Pfizer Inc. - Menarini Group - Acura Pharmaceuticals, Inc. - Elite Pharmaceuticals, Inc. - Charleston Laboratories, Inc. - Trevena, Inc. - QRxPharma Limited - KemPharm, Inc. - TheraQuest Biosciences, LLC Drug Profiles - PTI-202 - (oxycodone naltrexone) - oxycodone ER - PTI-721 - (morphine oxycodone) - NKTR-194 - levorphanol tartrate ER - buprenorphine hydrochloride ER - (dexketoprofen trometamol tramadol hydrochloride) - hydromorphone IR - E-58425 - HS-731 - (promethazine hydrocodone acetaminophen) - (oxycodone hydrochloride naltrexone hydrochloride) Extended Release - TRV-734 For more information visit http://www.researchandmarkets.com/research/xl...erate_pain
QRxPharma Completes A$11.6 Million Capital Raising
PR Newswire - Fri Dec 13, 8:00AM CST
QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) today announced the successful completion of its Share Purchase Plan (SPP) to existing shareholders raising A$4.1 million. The SPP was well oversubscribed with over 550 applications received. The SPP was originally planned for A$2.5 million however given the volume of support from shareholders for the SPP the Company has elected to take A$1.6 million in oversubscriptions, for a total of A$4.1 million and representing 6,810,363 shares. This A$4.1 million represents 75% of total applications monies received under the SPP and the Company has scaled back all allocations under the SPP by 25% in determining the final allocations to all participating shareholders.
QRxPharma Announces 25 May 2014 as New PDUFA Date for MOXDUO® NDA
PR Newswire - Wed Dec 11, 8:00AM CST
QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today that the United States Food and Drug Administration (FDA) has established 25 May 2014 as the new Prescription Drug User Fee Act (PDUFA) date for action on the Company's refiled New Drug Application (NDA) for immediate release MOXDUO. The FDA will schedule an Advisory Committee meeting prior to this date, and assuming approval, the Company plans to launch the product in the US in the second half of 2014.
QRxPharma Announces MOXDUO License Deal In Israel
PR Newswire - Wed Nov 27, 8:00AM CST
Signs License Agreement with Teva for Commercialisation in Israel
QRxPharma Refiles MOXDUO® New Drug Application with the FDA
PR Newswire - Tue Nov 26, 8:00AM CST
QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today that the Company resubmitted its MOXDUO® New Drug Application (NDA). At a meeting in early October, the United States Food and Drug Administration (FDA) provided QRxPharma with guidance on its requirements for the NDA refiling as well as data validation documentation.
QRxPharma Announces Successful Completion Of A$7.5 Million Placement
PR Newswire - Wed Nov 13, 8:00AM CST
QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) ("QRxPharma") announced today the successful completion of a Placement to institutional and sophisticated investors, raising A$7.5 million ("Placement"). The oversubscribed Placement was well supported primarily by existing shareholders plus some new investors. The Company also announced a Share Purchase Plan of up to A$2.5 million ("SPP") for existing shareholders to participate in this capital raise.
OTCM ADR Index Up 11.12% in Q3 2013, 12.75% Year-to-Date
PR Newswire - Thu Oct 17, 9:45AM CDT
OTC Markets Group Inc. (OTCQX: OTCM) today announced that the OTCM ADR Index (Bloomberg/Reuters: OTCDR; Thomson: DFCDR), the only index exclusively tracking American Depositary Receipts (ADRs) trading on the OTCQX®, OTCQB® and OTC Pink® marketplaces, rose 11.12% in the third quarter 2013, to close at 1,502 on September 30, 2013, compared to the MSCI EAFE which rose 9.86% during the same time period. The OTCM ADR Index, which is powered by BNY Mellon DR Indices and is comprised of more than 600 global companies from 38 countries across 10 industries, is up 12.75% year-to-date.
QRxPharma Extends MOXDUO® License With Aspen
PR Newswire - Tue Oct 15, 8:00AM CDT
QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today the execution of a licensing agreement with Aspen Pharmacare Holdings Limited (JSE: APN), for the commercialisation rights to immediate release MOXDUO in South Africa. On 11 September 2013 QRxPharma announced a licensing deal with Aspen's Australian subsidiary for the Australia, New Zealand and Oceania commercialisation rights to immediate release MOXDUO. That agreement also provided Aspen an option to enter into a license for the territory of South Africa, which Aspen has now exercised.
QRxPharma Reports Positive Meeting With The FDA On MOXDUO®
PR Newswire - Wed Oct 09, 8:00AM CDT
QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today the results of its meeting on October 3 with the United States Food and Drug Administration (FDA) to discuss the Company's MOXDUO New Drug Application (NDA). At the end-of-review meeting, the FDA provided the Company with a more complete understanding of their requirements for submission of the revised NDA and data validation documentation.
QRxPharma Announces MOXDUO® License With Aspen
PR Newswire - Wed Sep 11, 8:00AM CDT
QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today execution of a licensing agreement with Aspen Pharma Pty Ltd, one of the Australian subsidiaries of Aspen Pharmacare Holdings Limited (JSE: APN), for the commercialisation rights to immediate release MOXDUO in Australia, New Zealand and Oceania. The agreement also provides an option to license the commercialisation rights to immediate release MOXDUO in South Africa. Aspen Pharmacare Holdings Limited is a South African multinational pharmaceutical company supplying branded and generic products in more than 150 countries. One in five prescriptions written in Australia is for an Aspen Group ("Aspen") distributed product and its Australian business contributes revenues of nearly A$1 billion per annum to Aspen.
Osteoarthritis Pain - Pipeline Review, H2 2013
M2 - Tue Sep 10, 3:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8frj9r/osteoarthritis) has announced the addition of the "Osteoarthritis Pain - Pipeline Review, H2 2013" report to their offering. 'Osteoarthritis Pain - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Osteoarthritis Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Osteoarthritis Pain. Scope - A snapshot of the global therapeutic scenario for Osteoarthritis Pain. - A review of the Osteoarthritis Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Osteoarthritis Pain pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Genzyme Corporation Johnson & Johnson Allergan, Inc. Amgen Inc. Sanofi-Aventis Eli Lilly and Company BioDelivery Sciences International, Inc. Pfizer Inc. Purdue Pharma L.P. Teva Pharmaceutical Industries Limited Menarini Group BioChemics, Inc. Addex Pharmaceuticals Elite Pharmaceuticals, Inc. POZEN Inc. Array BioPharma Inc. Futura Medical plc. Transition Therapeutics Inc. Palau Pharma S.A Neurotune AG QRxPharma Limited and much more... For more information visit http://www.researchandmarkets.com/research/8f...oarthritis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
FDA Schedules Review Meeting With QRxPharma Regarding MOXDUO® NDA
PR Newswire - Fri Sep 06, 8:00AM CDT
QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today the United States Food and Drug Administration (FDA) has scheduled a meeting on 3 October to discuss the Company's MOXDUO New Drug Application (NDA) for the treatment of moderate to severe acute pain. The meeting was granted by the FDA after issuance of a Complete Response Letter (CRL) last month, and will focus on outstanding issues that need to be addressed in the revised NDA and data validation documentation.
Acute Pain - Pipeline Review, H2 2013 Reviews Key Players Involved In the Therapeutic Development for Acute Pain
M2 - Thu Sep 05, 9:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3cmj8z/acute_pain) has announced the addition of the "Acute Pain - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Acute Pain - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Acute Pain, complete with latest updates, and special features on late-stage and discontinued projects. Acute Pain - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Acute Pain. - A review of the Acute Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Acute Pain pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - AcelRx Pharmaceuticals, Inc. - Anavex Life Sciences Corp. - AngioChem Inc. - Array BioPharma Inc. - Cara Therapeutics, Inc. - Charleston Laboratories, Inc. - CombinatoRx, Incorporated - Cytogel Pharma, LLC - Encore Therapeutics Inc. - Esteve Group - Grunenthal GmbH - Intas Pharmaceuticals Ltd. - Iroko Pharmaceuticals, LLC - Madeira Therapeutics - Menarini Group - Nektar Therapeutics - NeuroTherapeutics Pharma Inc. - Nuvo Research Inc. - Orexo AB - Pacira Pharmaceuticals, Inc. - Pfizer Inc. - QRxPharma Limited - RaQualia Pharma Inc. - Sigma-Tau S.p.A. - Trevena, Inc. For more information visit http://www.researchandmarkets.com/research/3cmj8z/acute_pain About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Dystonia - Pipeline Review, H2 2013 Report Features Players such as Addex Pharmaceuticals and QRxPharma Limited
M2 - Thu Sep 05, 9:53AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vr9rld/dystonia) has announced the addition of the "Dystonia - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Dystonia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Dystonia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Dystonia. Dystonia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Dystonia. - A review of the Dystonia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Dystonia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - Addex Pharmaceuticals - QRxPharma Limited For more information visit http://www.researchandmarkets.com/research/vr9rld/dystonia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Duchenne Muscular Dystrophy - Pipeline Review, H2 2013
M2 - Mon Sep 02, 9:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dxghnf/duchenne_muscular) has announced the addition of the "Duchenne Muscular Dystrophy - Pipeline Review, H2 2013" report to their offering. 'Duchenne Muscular Dystrophy - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Duchenne Muscular Dystrophy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Duchenne Muscular Dystrophy. Scope - A snapshot of the global therapeutic scenario for Duchenne Muscular Dystrophy. - A review of the Duchenne Muscular Dystrophy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Duchenne Muscular Dystrophy pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Genzyme Corporation Johnson & Johnson Allergan, Inc. Amgen Inc. Sanofi-Aventis Eli Lilly and Company BioDelivery Sciences International, Inc. Pfizer Inc. Purdue Pharma L.P. Teva Pharmaceutical Industries Limited Menarini Group BioChemics, Inc. Addex Pharmaceuticals Elite Pharmaceuticals, Inc. POZEN Inc. Array BioPharma Inc. Futura Medical plc. Transition Therapeutics Inc. Palau Pharma S.A Neurotune AG QRxPharma Limited Iroko Pharmaceuticals, LLC and many more.... For more information visit http://www.researchandmarkets.com/research/dx...e_muscular About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
QRxPharma Receives Complete Response Letter From FDA Regarding MOXDUO® NDA
PR Newswire - Tue Aug 27, 6:24PM CDT
Additional time required to prepare and review respiratory data from Study 022
QRxPharma Announces Collaboration With Aesica
PR Newswire - Mon Jul 22, 6:00AM CDT
QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today execution of a Collaboration Agreement with Aesica Formulation Development Limited, a subsidiary of Aesica Pharmaceuticals Limited, for the world-wide promotion of QRxPharma's proprietary Stealth Beadlets® abuse deterrence technology. Aesica supplies pharmaceutical contract development and manufacturing services globally and operates six manufacturing sites across the UK, Germany and Italy. Aesica offers controlled drug services across the supply chain for which abuse or diversion may occur and is actively building relationships for supplying controlled drug Active Pharmaceutical Ingredients (APIs) and finished dose products to market.
QRxPharma Updates MOXDUO® NDA Review
PR Newswire - Wed Jun 26, 8:14AM CDT
QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today the planned 17 July 2013 US Food and Drug Administration (FDA) Advisory Committee meeting to consider the MOXDUO combination opioid analgesic New Drug Application (NDA) will be delayed in order to allow the Company and the FDA time to fully consider results of recent findings for Study 022. The NDA was re-filed in late February 2013, with the original Advisory Committee meeting scheduled for 17 July 2013 and the Prescription Drug User Fee Act (PDUFA) date was 26 August 2013.
Back Pain - Global Pipeline Review Report, H1 2013 Edition
M2 - Wed Jun 19, 10:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v9vbt8/back_pain) has announced the addition of the "Back Pain - Pipeline Review, H1 2013" report to their offering. 'Back Pain - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Back Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Back Pain. Scope - A snapshot of the global therapeutic scenario for Back Pain. - A review of the Back Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Back Pain pipeli
Century21.com Is The No. 1 Most Visited Real Estate Franchise Website
PR Newswire - Thu Jan 16, 8:08AM CST
Century 21 Real Estate LLC, the franchisor of the world's largest residential real estate sales organization, announced today that its website - century21.com - has become the No. 1 "most visited" real estate franchise website. According to comScore, Inc., a global leader in digital measurement and analytics, century21.com attracted more unique visitors than any other real estate franchise brand site in every month of 2013. In fact, century21.com holds a commanding lead in the number of unique website visitors in 2013 with 25.3 million for the entire year, which was approximately 10 million unique visitors higher than the next-closest national franchise brand. In a year where the industry average for all real estate sites was a 1% gain in total unique website visitors, CENTURY 21 posted a 49% year-over-year increase.
Global Moderate Pain Pipeline Review Report - H2 2013
M2 - Fri Dec 20, 8:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/xlmgdg/moderate_pain) has announced the addition of the "Moderate Pain - Pipeline Review, H2 2013" report to their offering. 'Moderate Pain - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Moderate Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Moderate Pain. Scope - A snapshot of the global therapeutic scenario for Moderate Pain. - A review of the Moderate Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Moderate Pain pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Involved in Moderate Pain Therapeutics Development - Nektar Therapeutics - Esteve Group - Pain Therapeutics, Inc. - Pfizer Inc. - Menarini Group - Acura Pharmaceuticals, Inc. - Elite Pharmaceuticals, Inc. - Charleston Laboratories, Inc. - Trevena, Inc. - QRxPharma Limited - KemPharm, Inc. - TheraQuest Biosciences, LLC Drug Profiles - PTI-202 - (oxycodone naltrexone) - oxycodone ER - PTI-721 - (morphine oxycodone) - NKTR-194 - levorphanol tartrate ER - buprenorphine hydrochloride ER - (dexketoprofen trometamol tramadol hydrochloride) - hydromorphone IR - E-58425 - HS-731 - (promethazine hydrocodone acetaminophen) - (oxycodone hydrochloride naltrexone hydrochloride) Extended Release - TRV-734 For more information visit http://www.researchandmarkets.com/research/xl...erate_pain
QRxPharma Completes A$11.6 Million Capital Raising
PR Newswire - Fri Dec 13, 8:00AM CST
QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) today announced the successful completion of its Share Purchase Plan (SPP) to existing shareholders raising A$4.1 million. The SPP was well oversubscribed with over 550 applications received. The SPP was originally planned for A$2.5 million however given the volume of support from shareholders for the SPP the Company has elected to take A$1.6 million in oversubscriptions, for a total of A$4.1 million and representing 6,810,363 shares. This A$4.1 million represents 75% of total applications monies received under the SPP and the Company has scaled back all allocations under the SPP by 25% in determining the final allocations to all participating shareholders.
QRxPharma Announces 25 May 2014 as New PDUFA Date for MOXDUO® NDA
PR Newswire - Wed Dec 11, 8:00AM CST
QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today that the United States Food and Drug Administration (FDA) has established 25 May 2014 as the new Prescription Drug User Fee Act (PDUFA) date for action on the Company's refiled New Drug Application (NDA) for immediate release MOXDUO. The FDA will schedule an Advisory Committee meeting prior to this date, and assuming approval, the Company plans to launch the product in the US in the second half of 2014.
QRxPharma Announces MOXDUO License Deal In Israel
PR Newswire - Wed Nov 27, 8:00AM CST
Signs License Agreement with Teva for Commercialisation in Israel
QRxPharma Refiles MOXDUO® New Drug Application with the FDA
PR Newswire - Tue Nov 26, 8:00AM CST
QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today that the Company resubmitted its MOXDUO® New Drug Application (NDA). At a meeting in early October, the United States Food and Drug Administration (FDA) provided QRxPharma with guidance on its requirements for the NDA refiling as well as data validation documentation.
QRxPharma Announces Successful Completion Of A$7.5 Million Placement
PR Newswire - Wed Nov 13, 8:00AM CST
QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) ("QRxPharma") announced today the successful completion of a Placement to institutional and sophisticated investors, raising A$7.5 million ("Placement"). The oversubscribed Placement was well supported primarily by existing shareholders plus some new investors. The Company also announced a Share Purchase Plan of up to A$2.5 million ("SPP") for existing shareholders to participate in this capital raise.
OTCM ADR Index Up 11.12% in Q3 2013, 12.75% Year-to-Date
PR Newswire - Thu Oct 17, 9:45AM CDT
OTC Markets Group Inc. (OTCQX: OTCM) today announced that the OTCM ADR Index (Bloomberg/Reuters: OTCDR; Thomson: DFCDR), the only index exclusively tracking American Depositary Receipts (ADRs) trading on the OTCQX®, OTCQB® and OTC Pink® marketplaces, rose 11.12% in the third quarter 2013, to close at 1,502 on September 30, 2013, compared to the MSCI EAFE which rose 9.86% during the same time period. The OTCM ADR Index, which is powered by BNY Mellon DR Indices and is comprised of more than 600 global companies from 38 countries across 10 industries, is up 12.75% year-to-date.
QRxPharma Extends MOXDUO® License With Aspen
PR Newswire - Tue Oct 15, 8:00AM CDT
QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today the execution of a licensing agreement with Aspen Pharmacare Holdings Limited (JSE: APN), for the commercialisation rights to immediate release MOXDUO in South Africa. On 11 September 2013 QRxPharma announced a licensing deal with Aspen's Australian subsidiary for the Australia, New Zealand and Oceania commercialisation rights to immediate release MOXDUO. That agreement also provided Aspen an option to enter into a license for the territory of South Africa, which Aspen has now exercised.
QRxPharma Reports Positive Meeting With The FDA On MOXDUO®
PR Newswire - Wed Oct 09, 8:00AM CDT
QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today the results of its meeting on October 3 with the United States Food and Drug Administration (FDA) to discuss the Company's MOXDUO New Drug Application (NDA). At the end-of-review meeting, the FDA provided the Company with a more complete understanding of their requirements for submission of the revised NDA and data validation documentation.
QRxPharma Announces MOXDUO® License With Aspen
PR Newswire - Wed Sep 11, 8:00AM CDT
QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today execution of a licensing agreement with Aspen Pharma Pty Ltd, one of the Australian subsidiaries of Aspen Pharmacare Holdings Limited (JSE: APN), for the commercialisation rights to immediate release MOXDUO in Australia, New Zealand and Oceania. The agreement also provides an option to license the commercialisation rights to immediate release MOXDUO in South Africa. Aspen Pharmacare Holdings Limited is a South African multinational pharmaceutical company supplying branded and generic products in more than 150 countries. One in five prescriptions written in Australia is for an Aspen Group ("Aspen") distributed product and its Australian business contributes revenues of nearly A$1 billion per annum to Aspen.
Osteoarthritis Pain - Pipeline Review, H2 2013
M2 - Tue Sep 10, 3:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8frj9r/osteoarthritis) has announced the addition of the "Osteoarthritis Pain - Pipeline Review, H2 2013" report to their offering. 'Osteoarthritis Pain - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Osteoarthritis Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Osteoarthritis Pain. Scope - A snapshot of the global therapeutic scenario for Osteoarthritis Pain. - A review of the Osteoarthritis Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Osteoarthritis Pain pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Genzyme Corporation Johnson & Johnson Allergan, Inc. Amgen Inc. Sanofi-Aventis Eli Lilly and Company BioDelivery Sciences International, Inc. Pfizer Inc. Purdue Pharma L.P. Teva Pharmaceutical Industries Limited Menarini Group BioChemics, Inc. Addex Pharmaceuticals Elite Pharmaceuticals, Inc. POZEN Inc. Array BioPharma Inc. Futura Medical plc. Transition Therapeutics Inc. Palau Pharma S.A Neurotune AG QRxPharma Limited and much more... For more information visit http://www.researchandmarkets.com/research/8f...oarthritis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
FDA Schedules Review Meeting With QRxPharma Regarding MOXDUO® NDA
PR Newswire - Fri Sep 06, 8:00AM CDT
QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today the United States Food and Drug Administration (FDA) has scheduled a meeting on 3 October to discuss the Company's MOXDUO New Drug Application (NDA) for the treatment of moderate to severe acute pain. The meeting was granted by the FDA after issuance of a Complete Response Letter (CRL) last month, and will focus on outstanding issues that need to be addressed in the revised NDA and data validation documentation.
Acute Pain - Pipeline Review, H2 2013 Reviews Key Players Involved In the Therapeutic Development for Acute Pain
M2 - Thu Sep 05, 9:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3cmj8z/acute_pain) has announced the addition of the "Acute Pain - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Acute Pain - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Acute Pain, complete with latest updates, and special features on late-stage and discontinued projects. Acute Pain - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Acute Pain. - A review of the Acute Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Acute Pain pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - AcelRx Pharmaceuticals, Inc. - Anavex Life Sciences Corp. - AngioChem Inc. - Array BioPharma Inc. - Cara Therapeutics, Inc. - Charleston Laboratories, Inc. - CombinatoRx, Incorporated - Cytogel Pharma, LLC - Encore Therapeutics Inc. - Esteve Group - Grunenthal GmbH - Intas Pharmaceuticals Ltd. - Iroko Pharmaceuticals, LLC - Madeira Therapeutics - Menarini Group - Nektar Therapeutics - NeuroTherapeutics Pharma Inc. - Nuvo Research Inc. - Orexo AB - Pacira Pharmaceuticals, Inc. - Pfizer Inc. - QRxPharma Limited - RaQualia Pharma Inc. - Sigma-Tau S.p.A. - Trevena, Inc. For more information visit http://www.researchandmarkets.com/research/3cmj8z/acute_pain About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Dystonia - Pipeline Review, H2 2013 Report Features Players such as Addex Pharmaceuticals and QRxPharma Limited
M2 - Thu Sep 05, 9:53AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vr9rld/dystonia) has announced the addition of the "Dystonia - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Dystonia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Dystonia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Dystonia. Dystonia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Dystonia. - A review of the Dystonia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Dystonia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - Addex Pharmaceuticals - QRxPharma Limited For more information visit http://www.researchandmarkets.com/research/vr9rld/dystonia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Duchenne Muscular Dystrophy - Pipeline Review, H2 2013
M2 - Mon Sep 02, 9:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dxghnf/duchenne_muscular) has announced the addition of the "Duchenne Muscular Dystrophy - Pipeline Review, H2 2013" report to their offering. 'Duchenne Muscular Dystrophy - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Duchenne Muscular Dystrophy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Duchenne Muscular Dystrophy. Scope - A snapshot of the global therapeutic scenario for Duchenne Muscular Dystrophy. - A review of the Duchenne Muscular Dystrophy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Duchenne Muscular Dystrophy pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Genzyme Corporation Johnson & Johnson Allergan, Inc. Amgen Inc. Sanofi-Aventis Eli Lilly and Company BioDelivery Sciences International, Inc. Pfizer Inc. Purdue Pharma L.P. Teva Pharmaceutical Industries Limited Menarini Group BioChemics, Inc. Addex Pharmaceuticals Elite Pharmaceuticals, Inc. POZEN Inc. Array BioPharma Inc. Futura Medical plc. Transition Therapeutics Inc. Palau Pharma S.A Neurotune AG QRxPharma Limited Iroko Pharmaceuticals, LLC and many more.... For more information visit http://www.researchandmarkets.com/research/dx...e_muscular About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
QRxPharma Receives Complete Response Letter From FDA Regarding MOXDUO® NDA
PR Newswire - Tue Aug 27, 6:24PM CDT
Additional time required to prepare and review respiratory data from Study 022
QRxPharma Announces Collaboration With Aesica
PR Newswire - Mon Jul 22, 6:00AM CDT
QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today execution of a Collaboration Agreement with Aesica Formulation Development Limited, a subsidiary of Aesica Pharmaceuticals Limited, for the world-wide promotion of QRxPharma's proprietary Stealth Beadlets® abuse deterrence technology. Aesica supplies pharmaceutical contract development and manufacturing services globally and operates six manufacturing sites across the UK, Germany and Italy. Aesica offers controlled drug services across the supply chain for which abuse or diversion may occur and is actively building relationships for supplying controlled drug Active Pharmaceutical Ingredients (APIs) and finished dose products to market.
QRxPharma Updates MOXDUO® NDA Review
PR Newswire - Wed Jun 26, 8:14AM CDT
QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today the planned 17 July 2013 US Food and Drug Administration (FDA) Advisory Committee meeting to consider the MOXDUO combination opioid analgesic New Drug Application (NDA) will be delayed in order to allow the Company and the FDA time to fully consider results of recent findings for Study 022. The NDA was re-filed in late February 2013, with the original Advisory Committee meeting scheduled for 17 July 2013 and the Prescription Drug User Fee Act (PDUFA) date was 26 August 2013.
Back Pain - Global Pipeline Review Report, H1 2013 Edition
M2 - Wed Jun 19, 10:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v9vbt8/back_pain) has announced the addition of the "Back Pain - Pipeline Review, H1 2013" report to their offering. 'Back Pain - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Back Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Back Pain. Scope - A snapshot of the global therapeutic scenario for Back Pain. - A review of the Back Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Back Pain pipeli
(0)
(0)Qrxpharma Ltd (QRXPF) Stock Research Links
Scroll down for more posts ▼